Companies / Industrials
IR
Ingersoll Rand
Industrial Machinery & Supplies & Components
Industrial Machinery & Supplies & ComponentsAnalysis in progress
In progress
We are decoding this company's strategy and relationships
New analyses are published every weekday. Founding members get them first.
Business at a glance
Operating-health scores describe reported fundamentals on a 0–100 scale. They are not a rating of the stock. How they work
Operating health69
Growth49
Profitability49
Cash generation82
Balance sheet76
Dilution control89
Key ratios and five-year financials
Latest quarter revenue YoY (2026-09-30)5.6%Revenue growth (FY)5.7%Revenue CAGR (3y)8.9%Gross margin43.6%Operating margin15.0%Net margin7.6%Free cash flow margin15.9%R&D / revenue1.5%Stock comp / revenue0.7%Net debt / operating cash flow2.61xCurrent ratio2.06Diluted share count change-1.5%
| Fiscal year ending | FY 2021-12 | FY 2022-12 | FY 2023-12 | FY 2024-12 | FY 2025-12 |
|---|---|---|---|---|---|
| Revenue | $5.2B | $5.9B | $6.9B | $7.2B | $7.7B |
| Gross profit | $2.0B | $2.3B | $2.9B | $3.2B | $3.3B |
| Operating income | $566M | $817M | $1.2B | $1.3B | $1.1B |
| Net income | $562M | $605M | $779M | $839M | $581M |
| Operating cash flow | $628M | $865M | $1.4B | $1.4B | $1.4B |
| Capital expenditure | $64M | $95M | $105M | $149M | $136M |
| Free cash flow | $564M | $771M | $1.3B | $1.2B | $1.2B |
| R&D | $74M | $91M | $108M | $117M | $114M |
| Stock-based comp | $87M | $79M | $52M | $59M | $53M |
| Buybacks | $737M | $261M | $263M | $261M | $1.0B |
| Dividends | $8M | $32M | $32M | $32M | $32M |
| Cash | $2.1B | $1.6B | $1.6B | $1.5B | $1.2B |
| Total debt | $2.8B | $2.7B | $2.7B | $4.8B | $4.8B |
| Equity | $9.0B | $9.2B | $9.8B | $10.2B | $10.1B |
StratGraph publishes general, impersonal research about public companies based on public filings. It is not investment advice, not a recommendation to buy, sell or hold any security, and not tailored to any reader's circumstances. Content may contain errors and may be partly generated with AI tools; verify against the original filings, which are linked. Authors may not trade securities discussed within the window set by our trading policy. Full disclaimer.